Patent · US Active

Chimeric antigen receptors that bind to SSEA4 and uses thereof

US10751399B2 · kind B2 · utility

0Cited by
0References
10Claims
0Family size

Assignee

Inventor

Key dates

Filing dateMar 20, 2018
Grant dateAug 25, 2020
Priority date
Expiry dateMar 20, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

An isolated nucleic acid that contains a nucleotide sequence that encodes the polypeptide of SEQ ID NO: 3. The polypeptide of SEQ ID NO: 3 specifically binds to stage-specific embryonic antigen 4 (SSEA4). Also disclosed is a recombinant cell comprising the isolated nucleic acid described above, a viral vector containing the above isolated nucleic acid, and an isolated polypeptide including the sequence of SEQ ID NO: 3. Provided as well is a chimeric antigen receptor (CAR) that includes a single chain Fv having the sequence of SEQ ID NO: 3 and specifically binding to SSEA4. Moreover, a method is disclosed for treating a tumor by transducing in vitro the T cells of a subject having a tumor expressing SSEA4 with a vector that encodes the CAR, expanding the transduced T cells, and infusing the expanded transduced T cells into the subject, whereby an anti-tumor T cell response is raised.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.